Biomarkers

Biomarkers and disease-modifying therapies make the biological cause of cognitive decline increasingly consequential. This seminar examines when an etiologic dementia diagnosis changes treatment, prognosis, counselling or eligibility for targeted therapy, and when a syndrome-based approach centred on symptoms, function and quality of life is more useful. Autopsy evidence illustrates the prevalence of mixed brain pathologies and informs diagnosis during life, including newer neuropathologic entities LATE and PART.

…immune modulation, disease biomarkers, bioengineering and therapeutic delivery. Studies range from proteomic profiling and diagnostic platforms to regenerative approaches and nucleic-acid therapies. An Education Day covers experimental design, isolation methods, MISEV guidance, career development and hands-on technology demonstrations; the scientific meeting includes oral prese

…therapeutic vulnerabilities, biomarkers, treatment response, relapse or survivorship, producing useful diagnostic, therapeutic or trial-enabling findings. The three-year term begins 1 April 2027. Applications are due 1 December 2026 at 13:00 U.S. Eastern Time.

…Discussion also covers biomarkers, scalability and the evidence needed to advance candidates beyond preclinical studies. Sunday 6 December, 14:00–15:30 Mountain Standard Time (Amer

…penetrance and effects on disease biomarkers; sub-studies can cover trial development, coordinated biobanking and the collection of imaging, digital or other high-value trial data. Amount and duration are flexible and set by each proposal. Standalo

…patient genetics, genomics and biomarkers with cellular and animal models, functional-genomic screening and measurements of morphology and transcription. Fellows develop independent projects during a three-year programme with a possible fourth year.

…and other human-relevant models; biomarkers and reliable bioanalytical assays; and integrating clinical trials with real-world data. Manufacturing sessions connect process understanding, analytical characterization and digital models with quality and scale-up. Formulation sessions address predictive design, advanced materials, targeted delivery and patient

Support development and validation of biomarkers for neurological and neuromuscular disorders using human samples or data. Projects progress from candidate biomarker development or confirmation to validation for an intended clinical use, with milestones governing the transition between R61 and R33 phases. The combined project may last up to five years; budgets must reflect the work and are not capped by the NOFO. The next new-application deadline is 20 October 2026, at 5 p.m. in the applicant organisation’s local time.

…mechanistic rationale and appropriate biomarkers. Phase 1 support is capped at USD 1 million; Phase 2–3 at USD 2 million over two to three years. Exceptional requests up to USD 3 million require case-by-case consideration. Letters of intent are due 20 October 2026 at 17:00 Eastern time (22 October for ISTAART members); invited full applications follow on 15 December (17 December for members).

…symptoms and guide future work on biomarkers.

Wearable sensors that detect and quantify biomarkers in retrievable biofluids (e.g., interstitial fluid, sweat, tears) provide information on human dynamic physiological and psychological states. This information can transform health and wellness by providing actionable feedback. Due to outdated and insufficiently sensitive technologies, current on-body sensing systems have capabilities limited to pH, and a few high-concentration electrolytes, metabolites, and nutrients. As such, wearable sensing systems cannot detect key low-concentration biomarkers indicative of stress, inflammation, metabo

…approach to identify potential biomarkers for improved diagnostic precision.Cerebrospinal fluid (CSF) and serum samples from 24 healthy controls, 48 MS patients, and 20 Non-MS patients with a range of diverse conditions, including infections, autoimmune disorders, inflammatory issues, and other neurological disorders were collected during lumbar puncture. NMR analysis on a

Aim: Over the past decade, our understanding of the transcriptional landscape in the brain has undergone a dogma-challenging expansion, revealing the intricate role of non-protein-coding RNAs (ncRNAs) in neural function, development, and disease. A large number of ncRNAs have been discovered and implicated in molecular regulatory processes involved in neural homeostasis and activity and seem to play crucial roles in neurodegenerative disorders and cancer. This study aims to assess the efficacy of in situ hybridization (ISH) in profiling long non-coding RNAs (lncRNAs) and circular RNAs (circRNA

Critical phenomena abound in nature, from forest fires and earthquakes to avalanches in sand and neuronal activity. Since the 2003 publication by Beggs & Plenz on neuronal avalanches, a growing body of work suggests that the brain homeostatically regulates itself to operate near a critical point where information processing is optimal. At this critical point, incoming activity is neither amplified (supercritical) nor damped (subcritical), but approximately preserved as it passes through neural networks. Departures from the critical point have been associated with conditions of poor neurologica

…can help to derive clinically useful biomarkers of dysfunction, and how these methods may guide surgical planning and prognostics.

…identifying theory-driven modifiable biomarkers focusing on these cognitive constructs with the ultimate goal to optimize and develop novel means of neu

Epilepsy is a common and disabling neurologic condition affecting adults and children that results from complex dysfunction of neural networks and is ineffectively treated with current therapies in up to one third of patients. This dysfunction can have especially severe consequences in pediatric age group, where neurodevelopment may be irreversibly affected. Furthermore, although seizures are the most obvious manifestation of epilepsy, the cognitive and psychiatric dysfunction that often coexists in patients with this disorder has the potential to be equally disabling. Given these challenges,

…of brain damage and symptoms, new biomarkers sensitive to early pathology, together with therapeutic strategies that include eliminating seed proteins and blocking cell-to-cell spread, are of vital importance.

The SynAGE committee members are thrilled to host ISYNC, the International SynAGE conference on healthy ageing, on 28-30 March 2022 in Magdeburg, Germany. This conference has been entirely organised from young scientists of the SynAGE research training group RTG 2413 (www.synage.de) and represents a unique occasion for researchers from all over the world to bring together and join great talks and sessions with us and our guests. A constantly updated list of our speakers can be found on the conference webpage: www.isync-md.de. During the conference, attendees will have access to a range of symp

Identifying biomarkers that predict current and future cognition may improve estimates of Alzheimer’s disease risk among cognitively unimpaired older adults (CU). In vivo measures of amyloid and tau protein burden and task-based functional MRI measures of core memory mechanisms, such as the strength of cortical reinstatement during remembering, have each been linked to individual differences in memory in CU. This study assesses whether combining CSF biomarkers with fMRI indices of cortical reinstatement improves estimation of memory function in CU, assayed using three unique tests of hippocamp

…disorders, availability of relevant biomarkers, poor predictability inanimal models, and high failure rates

…detected on structural MRI and used as biomarkers to determine the extent of cerebrovascular pathology. These biomarkers are associated with cognitive difficulties and increase the risk of dementia for the same level of neurodegenerative pathology. Given that some of the risk factors for cerebrov

…heterogeneity of DLB with multi-modal biomarkers is critical for the design of clinical trials that target each pathology early in the disease at a time when prevention or delaying the transition to dementia is possible. Furthermore, longitudinal evaluation of multi-modal biomarkers contributes to our understanding of the type and extent of the pathologic progression and serves to characterize the temp

Adult hippocampal neurogenesis is implicated in memory formation and mood regulation. The Thuret lab investigates environmental and molecular mechanisms controlling the production of these adult-born neurons and how they impact mental health. We study neurogenesis in healthy ageing as well as in the context of diseases such as Alzheimer’s and depression. By approaching neurogenesis in health and disease, the strategy is two folds: (i) Validating the neurogenic process as a target for prevention and pharmacological interventions. (ii) Developing neurogenesis as a biomarker of disease prediction